Skip to main content
Toggle navigation
FR
EN
Drupal
Main navigation EN
About Crossject
Who we are
Governance
R&D
Our technology
ZENEO®: needle-free technology
Products under development
Our supply chain
Therapeutic areas
Epileptic seizure
Acute adrenal crisis
Anaphylactic shock
Severe asthma crisis
Migraines and cluster headaches
Opioid overdose
Rheumatoid arthritis
Main navigation 2 EN
Finances
Profile
Analyst coverage
Financial releases
News
Our news
Press releases
Careers
Working at Crossject
Contact
Search
Search
Enter the terms you wish to search for.
Home
Finances
Financial releases
Financial releases
Release date
Min
Max
Year
All
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
Apply
2018/02/01
FDA grants orphan-drug designation to ZENEO® Midazolam
Read the release
2017/12/07
Business update
Read the release
2017/09/21
Interim 2017 results and business update
Read the release
2017/06/08
Business update Confirmation of the schedule of marketing authorisation filings
Read the release
2017/03/16
CROSSJECT receives €2.9M from Bpifrance as part of the PIAVE financing
Read the release
2017/03/06
CROSSJECT receives authorization to conduct Zeneo® Midazolam bioequivalence study
Read the release
2017/02/20
CROSSJECT boosts its US commercial development efforts
Read the release
2016/11/17
CROSSJECT unveils its strategic choices and new roadmap
Read the release
2016/05/10
CROSSJECT - AFPric STUDY: PATIENTS APPROVE NEEDLE-FREE INJECTION
Read the release
2015/12/09
CROSSJECT: Partnership agreement for ZENEO® Methotrexate in China with Xi’an Xintong Pharmaceutical Research
Read the release
Pagination
First page
« First
Previous page
‹ Previous
Page
1
Page
2
Page
3
Page
4
Page
5
Page
6
Page
7
Current page
8
Page
9
Next page
Next ›
Last page
Last »
